February 27, 2013

Serialization in Pharmaceuticals

Serialization in Pharmaceuticals

Serialization provides many benefits in addition to regulatory compliance, including improving patient safety, protecting corporate reputation, enhancing corporate social responsibility, and providing a competitive advantage. There is also value in data collected through serialization efforts. Manufacturers are discovering different ways to make best use of the data being returned by their supply chain partners.

Moreover, counterfeiting of drugs and medical devices costs the pharmaceutical and medical device industry billions of dollars annually in lost revenues. This loss is amplified by the serious threats fake drugs pose to the health and safety of consumers.

Join our speaker from Bristol-Myers Squibb, one of the first companies to understand the multiple benefits of item level serialization, as he examines serialization and its use in fighting counterfeit drugs.

A live Q&A session with the audience will follow the presentation.

Professionals from pharmaceutical, biotechnology and medical device companies with responsibilities and interests in the following areas:

• Supply Chain Management
• Regulatory Compliance
• State Reporting
• Business Analysis and Development
• Finance
• Legal and Regulatory Affairs

• Government Affairs
• Sales & Marketing
• Strategic Planning and Operations
• Commercial Operations
• IT

Daljeet Sahni currently works in the Global Supply Chain organization at Bristol-Meyers Squibb and has over 18 years experience in developing and executing strategies across a range of industries including Pharmaceuticals, Financial and Technology.

Mr. Sahni has an expert’s view of supply chain management and Serialization as a leader at Bristol-Meyers Squibb. He joined Bristol-Myers Squibb in 2011 to lead two major segments of BMS’s Global Serialization Initiative. Mr. Sahni leads the Data segment, which is responsible for establishing the data governance standards that will guide the Serialization program; and he also leads the Market Regulations segment, implementing a market monitoring process, executed by BMS’s global network of regulatory experts. As Serialization regulations evolve and mature country-to-country, Mr. Sahni establishes BMS’s response and action plans for the Serialization approach in these markets.

Prior to BMS, Mr. Sahni held leadership roles at Merck, Radian, AstraZeneca, Oracle and Bank of America (formerly MBNA). Daljeet has a master’s degree in Computer Science and received his MBA from the University of Delaware.